Mitchell K. Higashi, Ph.D.
Affiliations: | 2001 | University of Washington, Seattle, Seattle, WA |
Area:
PharmacyGoogle:
"Mitchell Higashi"Parents
Sign in to add mentor| David L. Veenstra | grad student | 2001 | University of Washington | |
| (Assessing the clinical and economic impact of genetic polymorphisms.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Cheng MM, Lu B, Hu SS, et al. (2009) Optimizing CAD diagnosis in China with CT angiography. Journal of Cardiovascular Computed Tomography. 3: 153-8 |
| Veenstra DL, Blough DK, Higashi MK, et al. (2005) CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clinical Pharmacology and Therapeutics. 77: 353-64 |
| Higashi MK, Veenstra DL, Langley PC. (2004) Health economic evaluation of non-melanoma skin cancer and actinic keratosis. Pharmacoeconomics. 22: 83-94 |
| Higashi MK, Veenstra DL. (2003) Managed care in the genomics era: assessing the cost effectiveness of genetic tests. The American Journal of Managed Care. 9: 493-500 |
| Higashi MK, Veenstra DL, del Aguila M, et al. (2002) The cost-effectiveness of interleukin-1 genetic testing for periodontal disease. Journal of Periodontology. 73: 1474-84 |
| Higashi MK, Veenstra DL, Kondo LM, et al. (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. Jama. 287: 1690-8 |
| Higashi M, Veenstra D, del Aguila M, et al. (2001) PEE2: THE COST-EFFECTIVENESS OF GENETIC TESTING FOR PERIODONTAL DISEASE. A PAYER'S PERSPECTIVE Value in Health. 4: 118-119 |
| Veenstra DL, Higashi MK, Phillips KA. (2000) Assessing the cost-effectiveness of pharmacogenomics. Aaps Pharmsci. 2: E29 |
| Veenstra DL, Higashi MK, Phillips KA. (2000) Assessing the comprehensiveness of pharmacogenomics Aaps Pharmsci. 2: 1-11 |